Clinical Trials Logo

Clinical Trial Summary

Percutaneous coronary intervention (PCI) is a standard treatment strategy for coronary artery disease (CAD). With the presence of myocardial ischemia, PCI reduces the risks of death, myocardial infarction (MI), and revascularization compared to medical therapy. However, the risk of future clinical events remains high, and about 10% of patients experienced further cardiovascular events after PCI. Several factors are associated with these poor outcomes. Well-known patient-related risk factors are diabetes mellitus, chronic kidney disease, left ventricular dysfunction, previous MI, and presentation with acute coronary syndrome. Procedure-related factors, such as stent under expansion, malposition, edge dissection, the number of the used stent, and total stent length, are also related to poor prognosis after PCI. Recent studies reported that fractional flow reserve (FFR) after coronary stenting, or post-PCI FFR, was associated with future clinical outcomes after PCI, and low post-PCI FFR value was associated with procedural factors. However, optimal cut-off values of post-PCI FFR ranged widely, from 0.86 to 0.96, and some studies reported the limited prognostic value of post-PCI FFR. This might result from differences in study populations, the definition of outcomes, type of stent used, and distribution of included vessels among previous studies. Previously, the investigators incorporated previous data into the International Post-PCI FFR registry and demonstrated the prognostic value of post-PCI FFR using the machine learning technique. However, the results were based on the two years follow-up of patients after PCI, and the prognostic value of post-PCI FFR in long-term outcomes is still uncertain. Therefore, the investigators planned to extend the International Post-PCI FFR registry to define the long-term prognostic implication of post-PCI FFR.


Clinical Trial Description

The investigators planned to extend the International Post-PCI FFR registry (NCT04684043) to explore the long-term prognostic value of post-PCI FFR. The International Post-PCI FFR registry (NCT04684043) already included the 2,200 patients who underwent PCI and measured post-PCI FFR between June 2011 and May 2018. As the clinical, angiographic, and physiologic data are already collected in the International Post PCI FFR registry, the investigators will further collect the most recent clinical outcome data until 2021.5 and incorporate them into the International Post-PCI FFR Extended registry. As the current study will evaluate clinical outcomes at 5 years, 2,128 patients who underwent PCI and measured post-PCI FFR between June 2011 and Nov 2016 will be included and studied. The investigators will request further clinical outcome data from 10 hospitals that provided the data for the International Post-PCI FFR registry before. A standardized form of a spreadsheet, including standardized definitions of variables, was used to collect the individual patient data from the principal investigators of each qualified registry. Patient clinical, angiographic, and physiologic data at the time of index PCI were recorded and already collected at Seoul National University Hospital. As clinical outcome data of 2 years of follow-up after index PCI are already collected in the International Post-PCI FFR registry (NCT04684043), clinical outcome data after 2 years of index PCI will be collected by medical records until 2021.5 of each hospital. All submitted data were double-checked by a central monitoring team in Seoul National University Hospital. All patients' identifying numbers are anonymized as "Subject_No" and the investigators will request the patients' clinical outcome data using these anonymized identifying numbers of the patients. Also, the investigators will share collected data with collaborators, using these numbers. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05672862
Study type Observational
Source Seoul National University Hospital
Contact
Status Completed
Phase
Start date September 6, 2021
Completion date December 31, 2022

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Completed NCT04492423 - VerifyNow® PRUTest® Cardiovascular Population Expected Values On-Drug Study
Completed NCT01205776 - EXCEL Clinical Trial N/A
Recruiting NCT01218776 - International Survey of Acute Coronary Syndromes in Transitional Countries
Completed NCT00046410 - Comparison of the Risk of Stroke With On- Versus Off-Pump Coronary Artery Bypass Grafting N/A
Recruiting NCT04390672 - Multivessel TALENT N/A
Completed NCT02784873 - High Intensity Interval Training in UK Cardiac Rehabilitation Programmes N/A
Completed NCT02948517 - Time Restricted Feeding for Weight Loss and Cardio-protection N/A
Not yet recruiting NCT02895009 - Hemostatic Compression Patterns After Transradial Coronary Intervention N/A
Recruiting NCT02859480 - Dose-dependent Effect of Rosuvastatin on Long-term Clinical Outcomes After PCI Phase 4
Completed NCT02510547 - Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial Phase 4
Withdrawn NCT02418143 - A Study to Obtain Additional Information on the Use of CorMatrix® CanGaroo ECM® Envelope
Completed NCT02382731 - Interventions to Support Long-Term Adherence aNd Decrease Cardiovascular Events Post-Myocardial Infarction N/A
Recruiting NCT01681381 - Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization N/A
Completed NCT02248415 - Administration of Warm Blood Cardioplegia With or Without Roller Pump N/A
Recruiting NCT01207167 - Mediators of Atherosclerosis in South Asians Living in America
Completed NCT02088138 - Functional Electrical Stimulation in Cardiac Patients N/A
Completed NCT02173067 - Anesthesia With Epinephrine in Diabetes Patients is Safe and Effective N/A
Completed NCT02133807 - Specific Lp(a) Apheresis for Regression of Coronary and Carotid Atherosclerosis Phase 3
Completed NCT00531011 - EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel Disease Phase 4